|
18 Oct 2026 |
Sharda Cropchem
|
Consensus Share Price Target
|
725.35 |
1196.00 |
- |
64.89 |
buy
|
|
|
|
|
03 Aug 2026
|
Sharda Cropchem
|
Khambatta Securities
|
725.35
|
1311.00
|
819.75
(-11.52%)
|
80.74 |
Buy
|
|
|
Sharda Cropchem Limited (SCL) started FY27 on a steady note with revenue up 9% y-o-y to Rs. 1,073.8 crore. Agrochemicals (85% of sales) grew 8% y-o-y to Rs. 915 crore while Non-agrochemicals, accounting 15% of the total sales grew 15% y-o-y to Rs. 159 crore.
|
|
30 Jul 2026
|
Sharda Cropchem
|
Anand Rathi
|
725.35
|
1350.00
|
820.00
(-11.54%)
|
86.12 |
Buy
|
|
|
Sharda Cropchem continued its strong earnings momentum in Q1FY27 despite higher y/y base. Revenue grew by 9% y/y to Rs10.7bn, owing to 12.7% y/y growth in price and forex, partially offset by 1.6/2.1% y/y decline in volume and product-mix.
|
|
18 May 2026
|
Sharda Cropchem
|
Khambatta Securities
|
725.35
|
1325.00
|
969.00
(-25.14%)
|
82.67 |
Buy
|
|
|
Sharda Cropchem Limited (SCL) ended the year FY26 on high note with revenue rising 21.9% y-o-y to Rs. 5,267.6 crore driven by volume growth of 13.4% y-o-y and favourable forex impact.
|
|
02 Feb 2026
|
Sharda Cropchem
|
Geojit BNP Paribas
|
725.35
|
1245.00
|
1126.90
(-35.63%)
|
Target met |
Buy
|
|
|
The RSI has surged into the bullish zone near 65, indicating strong momentum; while this suggests elevated activity, it also reflects renewed buying strength following the breakout. The MACD has turned positive, with a bullish crossover and a rising histogram, confirming...
|
|
02 Feb 2026
|
Sharda Cropchem
|
Khambatta Securities
|
725.35
|
1299.00
|
987.80
(-26.57%)
|
79.09 |
Buy
|
|
|
Sharda Cropchem Limited (SCL) reported a solid revenue growth of 38.7% y-o-y in 3Q FY26, reaching Rs 1,288.8 crore. This growth was primarily driven by volume growth of 14.4% and change in the product mix.
|
|
30 Jan 2026
|
Sharda Cropchem
|
Anand Rathi
|
725.35
|
1330.00
|
1035.85
(-29.98%)
|
83.36 |
Buy
|
|
|
Sharda Cropchem continued to outperform in Q3FY26, aided by healthy, 14% y/y volume growth, positive product-mix and favourable forex and market-share gain in its key regions.
|
|
05 Dec 2025
|
Sharda Cropchem
|
FundsIndia
|
725.35
|
1045.00
|
868.25
(-16.46%)
|
Target met |
Buy
|
|
|
Edge: High-entry-barrier regulatory portfolio + scalable global network
|
|
04 Nov 2025
|
Sharda Cropchem
|
Khambatta Securities
|
725.35
|
1184.00
|
816.80
(-11.20%)
|
Target met |
Buy
|
|
|
SCL reported a robust performance in 2Q FY26, driven by strong volume growth and margin expansion. The Company remains optimistic about a gradual recovery in the global agrochemical market, noting that inventories have normalized across distribution channels.
|
|
01 Nov 2025
|
Sharda Cropchem
|
Anand Rathi
|
725.35
|
1250.00
|
864.70
(-16.12%)
|
Target met |
Buy
|
|
|
Healthy, 35% y/y, volume growth and market-share gains in its key regions drove Sharda Cropchem’s Q2 results. Growth improved on better demand particularly in NAFTA and Europe coupled with near complete de-stocking across major regions.
|
|
21 Aug 2025
|
Sharda Cropchem
|
Khambatta Securities
|
725.35
|
1162.00
|
951.80
(-23.79%)
|
Target met |
Buy
|
|
|
Sharda Cropchem Limited (SCL) reported a 25% y-o-y increase in total revenue for 1Q FY26, reaching Rs 984.8 crore.
|
|
28 Jul 2025
|
Sharda Cropchem
|
Anand Rathi
|
725.35
|
1250.00
|
1090.45
(-33.48%)
|
Target met |
Buy
|
|
|
Healthy, 13% y/y, volume growth and market-share gains in its key regions drove Sharda Cropchem’s Q1 results. Growth improved on the back of better demand scenario particularly in Europe and a near complete destocking across major regions.
|
|
03 Jun 2025
|
Sharda Cropchem
|
Khambatta Securities
|
725.35
|
793.00
|
764.90
(-5.17%)
|
Target met |
Hold
|
|
|
Sharda Cropchem Limited (SCL) reported solid growth in 4Q FY25 as revenues increased by 39.4% y-o-y to Rs 1,828.5 crore. This robust quarterly growth was mirrored by a strong overall top-line performance for the entirety of FY25.
|
|
05 Mar 2025
|
Sharda Cropchem
|
Anand Rathi
|
725.35
|
730.00
|
540.00
(34.32%)
|
Target met |
Buy
|
|
|
We recently met Sharda Cropchem’s Chairman and MD, Mr R V Bubna to gauge the business outlook. Management is confident of achieving double-digit revenue growth (guidance raised 26% y/y post Q3 results vs. 15-20% earlier) in FY25, particularly due to volumes and penetration into new markets.
|
|
27 Jan 2025
|
Sharda Cropchem
|
Anand Rathi
|
725.35
|
730.00
|
569.10
(27.46%)
|
Target met |
Buy
|
|
|
A gradual price increase, volume growth across regions and a good product mix drove Sharda Cropchem’s better-than-expected Q3 results. Growth would improve ahead as de-stocking is now complete
|
|
27 Jan 2025
|
Sharda Cropchem
|
Khambatta Securities
|
725.35
|
770.00
|
569.10
(27.46%)
|
Target met |
Buy
|
|
|
? Sharda Cropchem Limited (SCL) reported solid growth in 3Q FY25 as revenues increased by 46.9% y-o-y to Rs 929.3 crore, fuelled by a robust increase in sales volume and a strategic price adjustment. Growth was observed across regions, with Europe and North America exhibiting strong performance. ? Gross margin expanded by 650 bps y-o-y to 32.7%.
|
|
29 Oct 2024
|
Sharda Cropchem
|
Khambatta Securities
|
725.35
|
729.00
|
710.25
(2.13%)
|
Target met |
Hold
|
|
|
Sharda Cropchem Limited (SCL) reported solid growth in 2Q FY25 as revenues increased by 33.8% y-o-y to Rs 776.9 crore. A volume growth of 21% y-o-y was driven by strong performance at the agrochemical segment with Europe being the key contributor.
|
|
30 Jul 2024
|
Sharda Cropchem
|
Khambatta Securities
|
725.35
|
676.00
|
557.05
(30.21%)
|
Target met |
Buy
|
|
|
Sharda Cropchem Limited (SCL) reported solid growth in 1Q FY25 as revenues increased by 23.1% y-o-y to Rs 785.1 crore. A volume growth of 41% y-o-y was driven by strong performance at the agrochemical segment.
|
|
25 Oct 2023
|
Sharda Cropchem
|
Prabhudas Lilladhar
|
725.35
|
470.00
|
411.25
(76.38%)
|
Target met |
Accumulate
|
|
|
|
|
24 Jul 2023
|
Sharda Cropchem
|
Prabhudas Lilladhar
|
725.35
|
540.00
|
481.35
(50.69%)
|
|
Accumulate
|
|
|
|
|
25 Jul 2022
|
Sharda Cropchem
|
Prabhudas Lilladhar
|
725.35
|
740.00
|
529.25
(37.05%)
|
|
Buy
|
|
|
|